Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

The United States Federal Trade Commission (FTC) filed an administrative complaint against the nation’s three largest ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Doctors say they have not seen anything like this since the emergence of statins to lower cholesterol. But do we know enough ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...

The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Tesla (TSLA 3.07%) is back. Shares of the electric vehicle (EV) maker plunged as much as 43% earlier this year. The stock has been on a roll since late April, though, soaring more ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...